Tissue-specific up-regulation of arginase i and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus

British Journal of Pharmacology

Volumn 172, Issue 19, 2015, Pages 4684-4698

  Pernow, J ^a   Kiss, A ^a   Tratsiakovich, Y ^a   Climent, B ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGINASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG; ARG2 PROTEIN, RAT; ARGINASE; ARGINASE I, RAT; NOS3 PROTEIN, RAT;

ARTICLE; CORONARY ARTERY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TISSUE SPECIFICITY; UPREGULATION; ANIMAL; CORONARY BLOOD VESSEL; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASODILATATION; WISTAR RAT;

ANIMALS; ARGINASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 1; MALE; MESENTERIC ARTERIES; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS, WISTAR; UP-REGULATION; VASODILATION;

EID: 84940956848     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13242     Document Type: Article

References (64)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The concise guide to pharmacology 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
2. Avogaro A, Albiero M, Menegazzo L, Kreutzenberg S, Fadini G, (2011). Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34: S285-S290.
3. Bagi Z, Feher A, Beleznai T, (2009). Preserved coronary arteriolar dilatation in patients with type 2 diabetes mellitus: implications for reactive oxygen species. Pharmacol Rep 61: 99-104.
4. Bagi Z, Feher A, Dou H, Broskova Z, (2013). Selective up-regulation of arginase-1 in coronary arteries of diabetic patients. Front Immunol 4: 293.
5. Beleznai T, Feher A, Spielvogel D, Lansman S, Bagi Z, (2011). Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol 300: 777-783.
6. Bivalacqua T, Hellstrom W, Kadowitz P, Champion H, (2001). Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 283: 923-927.
7. Chandra S, Romero M, Shatanawi A, Alkilany M, Caldwell R, Caldwell R, (2012). Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br J Pharmacol 165: 506-519.
8. Cheriyan J, Webb A, Sarov-Blat L, Elkhawad M, Wallace S, Mäki-Petäjä K, et al. (2011). Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123: 515-523.
9. Chuaiphichai S, McNeill E, Douglas G, Crabtree M, Bendall J, Hale A, et al. (2014). Cell-autonomous role of endothelial GTP cyclohydrolase 1 and tetrahydrobiopterin in blood pressure regulation. Hypertension 64: 530-540.
10. Climent B, Moreno L, Martínez P, Contreras C, Sánchez A, Pérez-Vizcaíno F, (2014). Upregulation of SK3 and IK1 channels contributes to the enhanced endothelial calcium signaling and the preserved coronary relaxation in obese Zucker rats. PLoS ONE 9: e109432.
11. Contreras C, Sánchez A, García-Sacristán A, Martínez M, Andriantsitohaina R, Prieto D, (2011). Preserved insulin vasorelaxation and up-regulation of the Akt/eNOS pathway in coronary arteries from insulin resistant obese Zucker rats. Atherosclerosis 217: 331-339.
12. De Vriese A, Verbeuren T, Van de Voorde J, Lameire N, Vanhoutte P, (2000). Endothelial dysfunction in diabetes. Br J Pharmacol 130: 963-974.
13. Desrois M, Clarke K, Lan C, Dalmasso C, Cole M, Portha B, et al. (2010). Upregulation of eNOS and unchanged energy metabolism in increased susceptibility of the aging type 2 diabetic GK rat heart to ischemic injury. Am J Physiol Heart Circ Physiol 299: H1679-H1686.
14. Dhar I, Dhar A, Wu L, Desai K, (2012). Arginine attenuates methylglyoxal- and high glucose-induced endothelial dysfunction and oxidative stress by an endothelial nitric-oxide synthase-independent mechanism. J Pharmacol Exp Ther 342: 196-204.
15. Durante W, (2013). Role of arginase in vessel wall remodeling. Front Immunol 4: 111.
16. Evans J, Goldfine I, Maddux B, Grodsky G, (2002). Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622.
17. Fujimoto H, Ohno M, Ayabe S, Kobayashi H, Ishizaka N, Kimura H, et al. (2004). Carbon monoxide protects against cardiac ischemia-reperfusion injury in vivo via MAPK and Akt-eNOS pathways. Arterioscler Thromb Vasc Biol 24: 1848-1853.
18. Gebremedhin D, Kaldunski M, Jacobs E, Harder D, Roman R, (1988). Influence of experimental diabetes on the mechanical responses of canine coronary arteries: role of endothelium. Cardiovasc Res 22: 537-544.
19. Grönros J, Jung C, Lundberg J, Cerrato R, Östenson C, Pernow J, (2011). Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 300: H1174-H1181.
20. Howangyin K, Silvestre J, (2014). Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler Thromb Vasc Biol 34: 1126-1135.
21. Kajikuri J, Watanabe Y, Ito Y, Ito R, Yamamoto T, Itoh T, (2009). Characteristic changes in coronary artery at the early hyperglycaemic stage in a rat type 2 diabetes model and the effects of pravastatin. Br J Pharmacol 158: 621-632.
22. Kassan M, Choi S, Galán M, Lee Y, Trebak M, Matrougui K, (2014). Enhanced p22phox expression impairs vascular function through p38 and ERK1/2 MAP kinase-dependent mechanisms in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 306: H972-H980.
23. Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Kiss A, Tratsiakovich Y, Gonon A, Fedotovskaya O, Lanner J, Andersson D, et al. (2014). The role of arginase and Rho Kinase in cardioprotection from remote ischemic perconditioning in non-diabetic and diabetic rat in vivo. PLoS ONE 9: e104731.
25. Knudson J, Dincer U, Bratz I, Sturek M, Dick G, Tune J, (2007). Mechanisms of coronary dysfunction in obesity and insulin resistance. Microcirculation 14: 317-338.
26. Koller A, Balasko M, Bagi Z, (2013). Endothelial regulation of coronary microcirculation in health and cardiometabolic diseases. Intern Emerg Med 8: 1-6.
27. Koltai M, Hadhazy P, Posa I, Kocsis E, Wickler G, Rosen P, et al. (1997). Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 34: 157-163.
28. Komers R, Schutzer W, Xue H, Oyama T, Lindsley J, Anderson S, (2007). Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats. Transl Res 150: 343-349.
29. Kövamees O, Shemyakin A, Pernow J, (2014). Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus. PLoS ONE 9: e103260.
30. Leo C, Hart J, Woodman O, (2011). Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes. Br J Pharmacol 162: 365-377.
31. Martin E, Bassi R, Marber M, (2015). p38 mitogen-activated protein kinase in cardioprotection-are we there yet? Br J Pharmacol 172: 2101-2113.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Ming X, Barandier C, Viswambharan H, Kwak B, Mach F, Mazzolai L, et al. (2004). Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110: 3708-3714.
34. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali J, (1993). Impairment of coronary vascular reserve in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42: 18-21.
35. Okon E, Chung A, Rauniyar P, Padilla E, Tejerina T, McManus B, et al. (2005). Compromised arterial function in human type 2 diabetic patients. Diabetes 54: 2415-2423.
36. Pandey D, Bhunia A, Oh Y, Chang F, Bergman Y, Kim J, et al. (2014a). OxLDL triggers retrograde translocation of arginase2 in aortic endothelial cells via ROCK and mitochondrial processing peptidase. Circ Res 115: 450-459.
37. Pandey D, Sikka G, Bergman Y, Kim J, Ryoo S, Romer L, et al. (2014b). Transcriptional regulation of endothelial arginase 2 by histone deacetylase 2. Arterioscler Thromb Vasc Biol 34: 1556-1566.
38. Paneni F, Beckman J, Creager M, Cosentino F, (2013). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34: 2436-2443.
39. Patel C, Rojas M, Narayanan S, Zhang W, Xu Z, Lemtalsi T, et al. (2013). Arginase as a mediator of diabetic retinopathy. Front Immunol 4: 173.
40. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
41. Pechánová O, Varga Z, Cebová M, Giricz Z, Pacher P, Ferdinandy P, (2014). Cardiac nitric oxide signalling in metabolic syndrome. Br J Pharmacol 172: 1415-1433.
42. Pernow J, Jung C, (2013). Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res 98: 334-343.
43. Romero M, Platt D, Tawfik H, Labazi M, El-Remessy A, Bartoli M, et al. (2008). Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102.
44. Romero M, Iddings J, Platt D, Ali M, Cederbaum S, Stepp D, et al. (2012). Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 302: H159-H166.
45. Santiago E, Contreras C, García-Sacristán A, Sánchez A, Rivera L, Climent B, et al. (2013). Signaling pathways involved in the H2O2-induced vasoconstriction of rat coronary arteries. Free Radic Biol Med 60: 136-146.
46. Sanz E, Fernández N, Monge L, Martínez M, Climent B, Diéguez G, et al. (2003). Effects of diabetes on the vascular response to nitric oxide and constrictor prostanoids: gender and regional differences. Life Sci 72: 1537-1547.
47. Shatanawi A, Lemtalsi T, Yao L, Patel C, Caldwell R, Caldwell R, (2015). Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway. Eur J Pharmacol 746: 106-114.
48. Shemyakin A, Kövamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, et al. (2012). Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126: 2943-2950.
49. Shi Y, Vanhoutte P, (2009). Reactive oxygen-derived free radicals are key to the endothelial dysfunction of diabetes. J Diabetes 1: 151-162.
50. Szerafin T, Erdei N, Fülöp T, Pasztor E, Edes I, Koller A, et al. (2006). Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res 99: e12-e17.
51. Taguchi K, Morishige A, Matsumoto T, Kamata K, Kobayashi T, (2012). Enhanced estradiol-induced vasorelaxation in aortas from type 2 diabetic mice may reflect a compensatory role of p38 MAPK-mediated eNOS activation. Pflugers Arch 464: 205-215.
52. Tawfik H, El-remessy A, Matragoon S, Ma G, Caldwell R, Caldwell R, et al. (2006). Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 319: 386-395.
53. Thengchaisri N, Hein T, Wang W, Xu X, Li Z, Fossum T, et al. (2006). Upregulation of arginase by H2O2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol 26: 2035-2042.
54. Toque H, Romero M, Tostes R, Shatanawi A, Chandra S, Carneiro Z, et al. (2010). p38 mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II treated mice. J Sex Med 7: 3857-3867.
55. Toque H, Nunes K, Yao L, Liao J, Webb R, Caldwell R, et al. (2013). Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med 10: 1502-1515.
56. Villalba N, Martínez P, Bríones A, Sánchez A, Salaíces M, García-Sacristán A, et al. (2009). Differential structural and functional changes in penile and coronary arteries from obese Zucker rats. Am J Physiol Heart Circ Physiol 297: H696-H707.
57. Weinbrenner C, Liu G, Cohen M, Downey J, (1997). Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 29: 2383-2391.
58. Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P, et al. (2004). Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res 63: 161-167.
59. Wu Z, Xiong Y, Gajanayake T, Ming X, Yang Z, (2012). p38 mitogen-activated protein kinase is required for glucosamine-induced endothelial nitric oxide synthase uncoupling and plasminogen-activator inhibitor expression. Circ J 76: 2015-2022.
60. Yang Z, Ming X, (2013). Arginase: the emerging therapeutic target for vascular oxidative stress and inflammation. Front Immunol 4: 149.
61. Yao L, Chandra S, Toque H, Bhatta A, Rojas M, Caldwell R, et al. (2013). Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 97: 509-519.
62. Yun J, Rocic P, Pung Y, Belmadani S, Carrao A, Ohanyan V, et al. (2009). Redox-dependent mechanisms in coronary collateral growth: the redox window hypothesis. Antioxid Redox Signal 11: 1961-1974.
63. Zhou J, Li P, Chen Q, Wei X, Zhao T, Wang Z, et al. (2015). Mitogen-activated protein kinase p38 induces HDAC4 degradation in hypertrophic chondrocytes. Biochim Biophys Acta 1853: 370-376.
64. Zhu W, Chandrasekharan U, Bandyopadhyay S, Morris S, DiCorleto P, Kashyap V, (2010). Thrombin induces endothelial arginase through AP-1 activation. Am J Physiol Cell Physiol 298: C952-C960.